51 results
S-1/A
EX-10.8
ALGS
Aligos Therapeutics Inc
9 Oct 20
IPO registration (amended)
5:26pm
to Executive, the Company shall reimburse Executive for the full amount of such taxes along with any additional tax due in connection with such reimbursement … policies with respect to documentation and reimbursement of such expenses. In agreeing to reimburse these expenses, the Company is not providing Executive
S-1/A
EX-10.9
ALGS
Aligos Therapeutics Inc
9 Oct 20
IPO registration (amended)
5:26pm
Executive for the full amount of such taxes along with any additional tax due in connection with such reimbursement. The Company reserves the right … and reimbursement of such expenses. In agreeing to reimburse these expenses, the Company is not providing Executive any tax advice. To the extent any
10-K
2020 FY
ALGS
Aligos Therapeutics Inc
23 Mar 21
Annual report
4:26pm
, as well as the pricing and reimbursement of our drug candidates, if approved;
the implementation of our business model and strategic plans for our … , expertise in research and development, manufacturing, nonclinical and clinical testing, and experience obtaining regulatory approvals and reimbursement
DRS
1skis92c3uo6
26 Aug 20
Draft registration statement
12:00am
10-Q
1i3fgl58zxp r6
25 Nov 20
Quarterly report
5:21pm
424B4
4nabxqfb
19 Oct 20
Prospectus supplement with pricing info
5:21pm
S-1
gjwouat063 3z
25 Sep 20
IPO registration
5:27pm
S-1/A
EX-10.12
9nznpkaj zrug
9 Oct 20
IPO registration (amended)
5:26pm